US Drug Recall Register

FDA Drug Recalls

2,277 recalls · Class II, newest first

Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection USP

Reason Lack of assurance of sterility: pinholes, within the finger boxes used during Form Fill Seal process resulting in leaks.

B Braun Medical INC NDC 0264-7800-10 D-0491-2025
Class II · Moderate risk Ongoing

Kimmtrak

Reason Subpotent Drug

Immunocore, LLC NDC 80446-0401-01 D-0614-2025
Class II · Moderate risk Ongoing

LIDOcaine HCL Sterile Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0001-0 D-0503-2025
Class II · Moderate risk Ongoing

LIDOcaine HCL Sterile Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0037-0 D-0502-2025
Class II · Moderate risk Ongoing

KETAmine Hydrochloride Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0007-2 D-0501-2025
Class II · Moderate risk Ongoing

KETAmine Hydrochloride Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0006-0 D-0500-2025
Class II · Moderate risk Ongoing

BUPIVAcaine HCL Sterile injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0036-0 D-0499-2025
Class II · Moderate risk Ongoing

LIDOcaine HCl Injection

Reason Lack of Assurance of Sterility: A recent FDA inspection revealed concerns with the sterile manufacturing process.

Tailstorm Health INC NDC 81483-0000-0 D-0498-2025
Class II · Moderate risk Ongoing

Testo-200

Reason Marketed Without an Approved NDA/ANDA

Advanced Pharmaceutical Technology, Inc. NDC 57377-200-01 D-0531-2025
Class II · Moderate risk Ongoing

Icosapent Ethyl Capsules 1 gram

Reason Failed Tablet/Capsule specifications; a product complaint was reported for burnt or melted capsules. This was determined to be a result of oxidation by leakage of capsule contents.

Zydus Pharmaceuticals (USA) Inc NDC 70710-1592-7 D-0497-2025
Class II · Moderate risk Ongoing

Gentamicin Injection

Reason Failed Stability Specifications: Out of specification results for the Color Absorbance test during 12 Month sample analysis.

Eugia US LLC NDC 55150-401-01 D-0472-2025
Class II · Moderate risk Ongoing

DOBUTamine Injection

Reason Discoloration; discolored solution from cracked vials

Pfizer Inc. D-0489-2025
Class II · Moderate risk Ongoing

Lacosamide Oral Solution

Reason Defective Container: This recall is being initiated due to a leaking unit stored horizontally.

Apotex Corp. NDC 60505-0405-4 D-0457-2025
Class II · Moderate risk Ongoing

0.9% Sodium Chloride Injection

Reason Lack of Assurance of Sterility

Fresenius Medical Care Holdings, Inc. NDC 49230-300-10 D-0490-2025
Class II · Moderate risk Ongoing

Metoclopramide Tablets

Reason Presence of foreign tablets/capsules.

Teva Pharmaceuticals USA, Inc NDC 0093-2203-01 D-0473-2025
Class II · Moderate risk Ongoing

Cephalexin for Oral Suspension

Reason Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ascend Laboratories, LLC NDC 67877-544-68 D-0469-2025
Class II · Moderate risk Ongoing

Cephalexin for Oral Suspension

Reason Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ascend Laboratories, LLC NDC 67877-544-88 D-0468-2025
Class II · Moderate risk Ongoing

Spectrum Advanced Gel Hand Sanitizer

Reason Subpotent product: Product has cloudy appearance and tested below assay label claim for 70% Ethyl Alcohol

Consumer Product Partners, LLC D-0458-2025
Class II · Moderate risk Ongoing

Acetaminophen Tablets

Reason cGMP deviations: Due to confirmed consumer complaints received with the observation of tablet discoloration (brown surface on tablets).

Aurobindo Pharma USA Inc NDC 72288-405-10 D-0471-2025
Class II · Moderate risk Ongoing

Nicotinamide adenine dinucleotide

Reason Lack of Assurance of Sterility

Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) D-0487-2025
Class II · Moderate risk Ongoing

Tirzepatide/Cyanocobalamin Injectable

Reason Lack of Assurance of Sterility

Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) D-0486-2025
Class II · Moderate risk Ongoing

Tirzepatide/Cyanocobalamin Injectable

Reason Lack of Assurance of Sterility

Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado) D-0485-2025